SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the company has named Taylor Sandison, M.D., M.P.H., its vice president, clinical development, to the position of acting chief medical officer, effective September 2, 2016. Dr. Sandison will replace Dirk Thye, M.D., Cidara’s previous chief medical officer, who has accepted a CEO position at a non-competing San Francisco Bay Area-based biotech company. Dr. Thye will continue to assist Cidara as a consultant.

“We wish Dirk all the best as he pursues his new endeavor, and we extend our sincere gratitude for his exceptional work in spearheading our antifungal development programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are pleased to have a highly experienced internal replacement in Taylor, allowing for a seamless transition of responsibilities. Taylor’s extensive experience has already been extremely valuable to our progress.”

Dr. Sandison has been with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Cubist Pharmaceuticals, Inc. from July 2014 to January 2015 and then, following Merck’s acquisition of Cubist, as senior medical director at Merck from February to October 2015. Dr. Sandison has also held positions at Trius Therapeutics and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, and M.D. and M.P.H. degrees from the University of Washington. He completed residency training at the University of Colorado and fellowship training at the University of Washington. Dr. Sandison holds board certifications in Infectious Diseases and Internal Medicine.

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial product portfolio comprises two formulations of the company's novel echinocandin, CD101. CD101 IV is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical is being developed for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Cidara’s clinical management change and Dr. Sandison’s ability to effectively replace Dr. Thye. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005355/en/

Source: Cidara Therapeutics, Inc.

INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA CONTACT:
Sam Brown Inc.
Mike Beyer, 312-961-2502
mikebeyer@sambrown.com